Sanofi SA (SASY.PA)
78.82EUR
11:35am EDT
€-1.05 (-1.31%)
€79.87
€79.94
€79.96
€78.58
2,159,117
2,863,787
€87.03
€59.45
SASY.PA
About
Overall
| Beta: | 0.50 |
| Market Cap (Mil.): | €106,843.60 |
| Shares Outstanding (Mil.): | 1,337.39 |
| Dividend: | 2.77 |
| Yield (%): | 3.47 |
Financials
| SASY.PA | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 25.44 | 32.01 | 32.18 |
| EPS (TTM): | 3.14 | -- | -- |
| ROI: | -- | 19.61 | 18.91 |
| ROE: | -- | 20.45 | 19.87 |
Sanofi's MS drugs get double boost in Europe
LONDON - Sanofi's hopes in the multiple sclerosis market received a double boost on Friday as the European regulator backed an injectable treatment and adopted a more positive stance toward a pill for the neurodegenerative disease.
UPDATE 1-Sanofi's MS drugs get double boost in Europe
* Follows Japan green light for diabetes drug Lyxumia (Adds details)
Sanofi wins EU green light for new MS drug Lemtrada
LONDON, June 28 - French firm Sanofi has won a European green light for its new multiple sclerosis medicine Lemtrada, after a quarter-century drug development saga.
Sanofi wins diabetes drug approval in Japan
PARIS, June 28 - French drugmaker Sanofi said it won approval from the Japanese government for its Lyxumia drug for the treatment of Type 2 diabetes in combination with basal insulin.
EU's drug data stance threatens investment: Sanofi CEO
BRUSSELS - A decision by Europe's drug regulator to release detailed data on drugs once a medicine is approved could discourage critical investment in crisis-hit Europe, Sanofi's chief executive said.
UPDATE 1-EU's drug data stance threatens investment -Sanofi CEO
* Viehbacher says companies may decide to invest elsewhere
UPDATE 1-Sanofi plans late-stage diabetes pen tests in 2014
PARIS, June 24 - French drugmaker Sanofi said it aims to start late-stage tests in the first half of 2014 for a pen-shaped device that combines two diabetes treatments and could help patients better control blood sugar levels.
Sanofi plans late-stage diabetes combo drug tests in 2014
PARIS - Sanofi aims to start late-stage tests for a pen device combining diabetes treatments Lantus and Lyxumia in the first half of 2014, according to slides posted on its website ahead of a presentation to investors on Monday.
Sanofi plans late-stage diabetes combo drug tests in 2014
PARIS, June 24 - Sanofi aims to start late-stage tests for a pen device combining diabetes treatments Lantus and Lyxumia in the first half of 2014, according to slides posted on its website ahead of a presentation to investors on Monday.
Sanofi's next-generation insulin shows edge over Lantus
PARIS - An improved version of Sanofi's blockbuster insulin Lantus is better than the older drug at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin, according two late-stage tests published on Saturday.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Finlabo SIM Spa
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
